Not surprisingly, pharmacological antagonists of the RAS, such as angiotensin-converting enzyme inhibitors (ACEi) or AT1R blockers (ARBs), constitute classical therapeutic approaches to control hypertension and end-organ damage, including the kidney (Carson et al., 2001; Dahlof et al., 2002; Viazzi et al., 2016). The gene discussed is AGTR1; the disease is Hypertension.